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Summary: Interactions between elastase Inhibitor complexes and synovial cells are of special interest, since,
in chronic joint diseases, granulocytes release large amounts of elastase into the synovial fluid and connective
tissue, where the proteinase is böund to cti-proteinase inhibitor and a2-macroglobulin. To study the effect of
elastase-a2-macroglobulin and elastase-arproteinase inhibitor complexes on the glycosaminoglycan metab-
olism of cultured synovial cells, we determined the distribution of [3H]glucosamine-labelled hyaluronate,
which represents the main synthesized glycosaminoglycan, and of 35SO4~-labelled chondroitin sulphate into
the intracellular, pericellular and extracellular compartments of the cell culture. Exposure of the synovial
cells to elastase-a2-inacroglobulin complexes leads to an enhanced synthesis and secretion of hyaluronate
and chondroitin sulphate, and also induces a rise of the fibronectin concentration in the medium. Analogous
but less pronounced effects are observed in the presence of elastase-arproteinase inhibitor complexes. Native
uncomplexed elastase, however, causes no significant changes in hyaluronate metabolism. An increase of
prostaglandin E2 in the culture medium during incubation with elastase inhibitor complexes occurs in parallel
to the stimulatory effect on glycosaminoglycan metabolism. Our results demonstrate that elastase, whose
enzymic activity is inactivated by the formation of complexes with fy -proteinase inhibitor or a2-macroglobulin,
nevertheless acts äs an inflammatory mediator, which in vitro induces metabolic changes closely resembling
the in vivo findings in inflammatory joint diseases.
Introduction teinase becomes bound to proteinase Inhibitors; in
T . „ . . ,. - . . serum about 90% is bound to <xrproteinase inhibitorIn mflammatöry jomt d,seases a v*ri#y öf proteolytic ^ ̂  w% t<j ro^obuün (10). Elastase.
enzymes are resppnsible for the degradation of mätnx tdftase inhibitor complexes are enzymatically
componepts of articular cartuage (1^4). Protemases . .. ,44^ u i u r r, * * . , ,. &. . ' . ', mactive (11), whereas a2-macroglobulm forms com-shown to be mvolved m connective tissue breakdown , \' - , u. , ,. „«0*· ,, . . - ' - . ^ , plexes with elastase, which are still enzymaticallyare the neutral protemäses, elastase, cathepsin G and . " tl , . u * * / i i„ , - , , ^ / i active towards small protem Substrates (molecular
collagenase, which are released from granulocytes . , innoo^ (i 2^
mäinly during phagocytosis, after cell death, and ex-
posure to fluid factors like complenient and interleu- Elastase inhibitor complexes are phagocytosed by
kinl(5 —8). In particular, elastase is released in large macrophages at the site of inflammation and are
amounts and is therefore of special pathogenic and removed from the blood circulation by tissue macro-
diagnostic importance (9). After release of elastase phages in liver and spieen (13). It has been shown
into the extracellular space, this catipnic serine pro- that fixed macrophages are activated by endocytosis
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of proteinase-a2-macroglobulin complexes to produce
and secrete neutral proteinases (14) and probably
prostaglandins. Thus, the disposal of elastase-a2-ma-
croglobulin complexes seems to be a way of amplify-
ing inflammation and might be involved in the Stimu-
lation of hepatic acute phase protein synthesis (15).
High levels of elastase complexed with proteinase
inhibitors are detectable in synovial fluids of patients
with chronic inflammatory joint diseases (16—18).
The concentration of elastase-arproteinase inhibitor
complexes, which are found in inflammatory synovial
fluids, is often extremely enhanced (up to 100 mg/1),
compared with those. in non-inflammatory synovial
fluids and normal plasma (50-150 g/l).
Detailed studies on the influence of elastase-protein-
ase inhibitor complexes on the metabolism of sur-
rounding connective tissue cells in the joint cavity are
still lacking. In the present work we used synovial
fibroblast cultures äs a defined model to investigate
the influence. of elastase-proteinase inhibitor com-
plexes on the metabolism of these connective tissue
cells in the synovial System.
Earle's salt and supplemented with penicillin (100 lU/ml), strep-
toraycin (100 mg/1), amphotericin B (2.5 g/l) and foetal calf
serum: volume fraction 0.2. A humidified atmosphere of 5%
CO2 in air was used. Medium changes were performed every
48h. After the third to fourth subculturing, 0.6 l O6 cells
were incubated in 25 cm2 culture flasks (Nunc) until confluent
monolayers with densities of about 0.6 l O5 cells/cm2 were
achieved. Subsequently, the cells were incubated for 24 h in
4.5 ml serum-depleted minimum essentia*! meditim, containing
platelet derived growth factor (0.64 U/ml), antibiotics and the
radioactive precursors [3]ghicosamine and 35SC>4~ in final con-
centrations of 56 kBq/1 and 0.56 MBq/1, respectively. During
the incubation time of 24 h the cell nuniber of the monolayers
remained constant.
The effect of elastase, elastase-aj-proteinase inhibitor com-
plexes, elastase-a2-macroglobulm complexes, ctt-proteinase in-
hibitor and a2-macroglobulin on the synovial cell metabolism
was studied using the following agent concentrations in the
culture mediuni: elastase (0.22, 2.24 and 22.4 nmol/1), elastaser
ctj-proteinase inhibitor complexes (25.1 and 251 nmol/1), elas-
tase-a2-macroglobulin complexes (11.5 and 115 nmol/1),. QJ-
proteinase inhibitor (1574 nmol/1), a2-macroglobulin (125
nmol/1), assuming relative molecular masses of 28 000, 53 000
and 725 000 for elastase, ctj-proteinase inhibitor and a2-macro-
globulin, respectively.
All experiments in the presence or absence of elastase proteinase
inhibitor complexes were performed in 14-fold parallel trials,
using 5 cultures for the Isolation of radioactive glycosaminogly-
cans and 3 cultures each for cpunting the celis, detennination




Human granulocyte elastase, a{ -proteinase inhibitor and a2-
macroglobulin are research products of the Biochemical Re-
search Department of E. Merck (Darmstadt, FRG). Eagle's
minimum essential medium (M EM), Earle's salt and foetal calf
serum were obtained from Flow Laboratories (Bonn, FRG),
platelet-derived-growth-factor (PDGF), type I, from Collabora-
tive Research Inc. (Waltham, Mass., USA), and the radio-
chemicals [3H]glucosamine (specific activity: 27.6 MBq/mmol)
and 35SOJ~ (specific activity: 1.2 GBq/mmol) from New Eng-
land Nuclear (NEN)-Chemicals (Dreieich, FRG). Hyaluronate
lyase, chondroitin AC lyase and chondroitin ABC lyase were
purchased from Seikagaku (Kogyo, Japan). Sephacryl S-400
was obtained from Pharmacia Fine Chemicals (Uppsala, Swe-
den).
Cell cul ture
Synovial cells were grown from tissue pieces excised from the
knee-joint capsule of a 30-year-old man during meniscectomy.
Cell cultivation was performed by a method described elsewhere
(19). The cells were detached from the synovial membrane by
incubation in 2.5 g/l trypsin in Earle's balanced salt sohition
for 15 min at room temperature on a magnetic stirrer. After
filtration (gauze filter) and centrifugation of the filtrate (400 g,
20 min) the pellet was suspended in culture medium (see below)
enriched with foetal caif serum to give a volume fraction of
0.2, and about 0.6 l O6 cells in 20 ml medium were placed
into each 25 ml Falcon culture flask (Nunc, Wiesbaden, FRG).
Culture conditions
Primary cultures of synovial fibroblasts were maintained at
37 °C in Eagle's minimum essential medium, modified with
Isolation of radioactive glycosaminoglycans
The radioactive peptidoglycosaminoglycans were isolated from
topographically distinct pools of the cell culture, äs described
elsewhere (19). Firstly, the mediuni, which represents the extra-
cellular compaftment, was removed and the cell layer rinsed 5
times with 5 ml phosphate-buffered saline. After treatment with
3 ml trypsin solution (see above) the dispersed cells were centri-
fuged (400 £,10 min, 4 °C), the supernate being the pericellular
compartment (tryptic fraction). After washing 3 times with
5 ml phosphate-buffered saline the pellet was processed äs the
intracellular compartment.
The material of the different pools was then subjected to proteo-
lytic digestion with pronase from Streptomyces griseus in phos-
phate-buffered saline (pH 7.5, 37 °C, 24 h) in a final concentra-
tion of 5 g/l (cell pellet) or 1.25 g/l (medium, tryptic fraction).
Subsequently, the 3 trial compartments were treated identically.
After addition of carrier glycosaminoglycans (hyahironic
acid:chondroitin sulphate = 2:1) and precipitation with a 4-
fold volume of ethanol saturated with sodium acetate, repeated
proteolysis of the precipitate with papain (specific activity: 30
U/mg, 15 U per test, pH 4.5, 56 °C, 24h) was carried out.
Precipitation of the protein with trichloroacetic acid (final
concentration 50 g/l) and centrifugation were followed by neu-
tralization and exhaustive dialysis of the supernate against
water and precipitation of the peptidoglycosaminoglycans with
cetylpyridinium Chloride (final concentration 10 g/l in 0.04
mol/1 NaCl). After Standing overnight at room temperature,
the sediment was obtained by centrifugation at 7500 g for 20
min. The precipitated cetylpyridinium chloride-glycosäminogly^
can complex was sohibilized in 2 mol/1 NaCl and ethanol (vol-
ume fraction 0.15 in water), and the glycosaminoglycans were
again precipitated with 4 volumes of ethanol.
Radioactivity was measured in a liquid scintillation counter
(Rackbeta 1217, LKB, Bromma, Sweden). Results were ex-
pressed äs radioactivity of 3H- or ^SOj'-labelled glycosamino-
glycans per mg protein.
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Determination of hyaluronate and chondroitin sul-
phate
For analysis of hyaluronate and chondroitin sulphate the puri-
fied precipitate containing the total glycosaminoglycans was
degraded with hyaluronate lyase, chondroitin AC lyase and
chondroitin ABC lyase, s described previously (20, 21). Radio-
activity was determined in precipitate and supernate.
Preparation of elastase-dj-proteinase inhibitor com-
plexes
Granulocyte elastase (1.5 mg; 0.054 μτηοΐ) was incubated at
37 °C with 1.5 mg (0.028 μπιοί) arproteinase inhibitor in the
presence of 0.5 ml 0.05 mol/1 sodium phosphate buffer (pH 6.4),
containing 0.5 mol/1 NaCl. After 3 h the incubation mixture was
subjected to gel filtration on sephacryl S-400 (column 16 χ 70
mm) and the elastase-arproteinase inhibitor-containing frac-
tions were pooled and concentrated to 5 ml by ultrafiltration
(Amicon PM-10). The concentration of complexed elastase was
determined by an enzyme immunoassay (22). The incubation
was performed in the presence of excess native elastase, since the
difference between the relative molecular masses of unbound
elastase and formed elastase-inhibitor complexes allows a com-
plete Separation of both in the subsequent gel filtration chroma-
tography.
Preparation of elastase-a2-macroglobulin complexes
Elastase-a2-macroglobulin complexes were prepared by incuba-
tion of 1.5 mg (0.054 μχηοΐ) granulocyte eiastase with 15 mg
a2-macroglobulin (0.021 μτηοΐ) in 0.5 ml 0.05 mol/1 sodium
phosphate buffer, 0.5 mol/1 NaCl (pH 6.4) for 3 h at 37 °C.
Subsequent purification of the complexes was achieved by gel
filtration on a Sephacryl S-400 column (16 χ 70 mm). Elastase-
a2-macroglobulin complex-contaimng fractions were pooled
and concentrated to 5 ml.
Other methods
Protein content was measured according to Lowry et al. (23)
with bovine serum albumin s a Standard. Glucose (24) and
lactate (25) were measured enzymatically using a centrifugal fast
analyzer Cobas Bio (Hoffmann-La R che, Basel, Switzerland).
Fibronectin was determined by radial immunodiffusion (LC-
Partigen plates, Behring Werke, Marburg, FRG); Prostaglandin
E2 was determined by radioimmunoassay using a commercial
kit (NEN chemicals). Cell numbers were detennined by exam-
ination of the hematoxylin-stained cell layer with a phase-
difference inverse microscope using an ocular reticule micro-
meter.
Statistical analysis
The significance of differences was checked by a Standard t-test
for dependent samples (26). P values < 0.02 were considered
significant.
Results ·
Effects of elastase-inhibitor complexes on
the metabolism of cultured synovial cells
Effect on hyaluronate
Elastase-inhibitor complexes stimulate the incorpo-
ration of the radiolabelled precursors [3H]glucosa-
mine and 35SO2" into the total glycosaminoglycans





















a) elastase-a2-macroglobulm complexes and
b) elastase-arproteinase inhibitor complexes
on the incorporation of [3H]glucosamine (o—c) and
35SO4"* (n —n) into total glycosaminoglycans of cul-
tured synovial cells. Mean and Standard deviation are
given.
More detailed Information about glycosaminoglycan
metabolism is obtained from the measurement of the
incorporation of radioactivity into both hyaluronate
and chondroitin sulphate (flg. 2). -Exposure of the
cultured synovial fibroblasts to elastase-a2-macroglo-
bulin complexes (11.5, 115 nmol/1) dose-dependently
stim lates the incorporation of [3H]glucosamine into
total hyalurpnate in a dose-dependent manner, es-
pecially in the extracellular pool (maximum increase
of about 70%), whereas at the same time the radio-
active hyaluronate of the intracellular and the pericel-
lular pool decreases by about 63% and 10%, respec-
tively.
The effects of elastase-arproteinase inhibitor com-
plexes on the metabolism of hyaluronate are similar
to those observed in the presence of elastase-a2-ma-
cr globulin complexes (flg. 2). However, compared
with elastase-a2-macroglobulin complexes, significant
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Fig. 2. Effect of elastase-a2-macroglobulin complexes and elas-
tase-dj-proteinase inhibitor complexes on hyaluronate
metabolism in cultured synovial fibroblasts. The radio-
labelled hyaluronate was isolated from topographically







































Fig. 3. Effect of elastase-a2-macroglobulin complexes and elas-
tase-arproteinase inhibitor eomplexes on the metab-
olism of chondroitin sulphate in cultured synovial fibro-
blasts. The radioactive labelled chondroitin sulphate
was isolated from topographically distinct poqls of the
cell culture. Mean and Standard deviation are given.
stimulatory effects of the elastase-arproteinase inhib-
itor complexes are observed only at higher molar
concentrations (extracellular radioactive hyaluronate
increases of about 49% at 251 nmol/l).
Effect on chondroitin sulphate
As shown by enzymatic analysis, glycosaminoglycans
secreted by cultured synovial fibroblasts are com-
posed of about 90% hyaluronate. The remaining
glycosaminoglycans consist of about 10% chon-
droitin sulphate, degraded by chondroitin AC lyase.
Dermatan sulphate was detectable only in trace
amounts.
In the presence of elastase-a2-macroglobulin com-
plexes and elastase-arproteinase inhibitor complexes,
the incorporation of 35SO|~ into total chondroitin
sulphate is enhanced (fig. 3). Especially the extracellu-
lar radiolabelled fraction is increased: about 72% and
110% during culturing with 115 nmol/l elastase-a2-
macroglobulin and 251 nmol/l elastase-di-proteinase
inhibitor complexes, respectively. However, at the
same time, the amourit of radioaetive chondroitin
sulphate in the cells and the pericellular space is
diminished by about 40% and 14%, respectively.
Effect on glycolysis
Elastase-inhibitor complexes cause a significant ift-
crease of glucose uptake and lactic acid production.
Glucose uptake increases from 3.42 ± 0.15 (Standard
deviation) μπιοΙ/106 cells in the absence of elastase-
a2-macroglobulin complexes to 3.99 ± 0.15 and 4.83
± 0.08 μmol/106 cells at complex concentrations of
11.5 and 115 nmol/l, respectively. The lactic acid
production rises from 6.91 ± 0.23 to 7.93 ± 0,41
and 9.96 ± 0.30. A similar but less pronounced effect
on glucose uptake and lactic acid production is found
in the presence of elastase-at-proteinase inhibitor
complexes at 251 nmol/l.
J. Clin. Chem. Clin. Biochem. / Vol. 25,1987 / No. 3
Kleesiek et al.: Efifect of elastase-proteinase Inhibitor complexes on glycosaminoglycan metabolism 155
Effect on prostaglandin £2
Addition of elastase-a2-macroglobulin complexes
(l l .5,115 nmol/1) and elastase-arproteinase inhibitor
complexes (25.1, 251 nmol/1) to the synovial fibro-
blast cultures leads to an increase of prostaglandin
E2 in the culture medium, which is more pronounced
in the presence of elastase-c^-macroglobulin com-
plexes (6-fold increase), whereas native elastase does
not show a significant effect (fig. 4).
Effect onßbronectin
The fibronectin concentration in the culture medium
is also affected by elastase inhibitor complexes. Ele-
vated complex concentrations are able to evoke a
strong Stimulation of the fibronectin concentration
in the culture medium: incubation with elastase-a2-
macroglobulin complexes (115 nmol/1) or with elas-
tase-aj-proteinase inhibitor complexes (251 nmol/1)
leads to a 12-fold or 6-fold increase of fibronectin
concentration, respectively (fig. 5). However, no
stimulatory effect was observed at lower concentra-
tions of the elastase-a2-macroglobulin and elastase-
cti-proteinase inhibitor complexes (11.5 and 25.1
nmol/1, respectively).
Culturing synovial cells in the presence of
native elastase, dj-proteinase inhibitor, or
a2-macroglobulin
Native uncomplexed elastase causes no significant
incorporation of pH]glucpse into hyaluronate (tab.
1). Only a moderate increase of 358 |~-incorporation
into extracellular chondroitin sulphate was found
when synovial fibroblasts were incubated with native
elastase (2.2, 22.4 nmol/1). In the presence of higher
concentrations of native elastase (224 nmol/1) a tryp-
sin-like effect was observed, evident by detachment
of the monolayer cells. In samples taken during the
incubation of the synovial fibroblasts with native
elastase no elastase-ai-pröteinase inhibitor complexes
were detectable by an enzyme immunoassäy (detec-
tion limit: 10 pmol/1), which indicates that np är
proteinase inhibitor was released by the cells in cul-
ture.
Concentrations öf ai-macroglobulin similar to those
found in synovial fluids from patients with chronic
joint diseases effect no changes on the glycosamino-
glycan metabolism. Native arproteinase inhibitor,
howeyer, strongly inhibits the incorporation of [3H]
glucosamine into hyaluronate (90% Inhibition of to-
tal hyaluronaie synthesis) and of 35SO|~~ into chon-
droitin sulphate (97% Inhibition), derived from the
different compartments of the cell culture (tab. 1).
10 100
c[nnr to l / ( ]
Fig. 4. Eflfect of granulocyte elastase (D — o), elastase-a2-ma-
croglobulin complexes (o —o), and elastase-arprotein-
ase inhibitor complexes (o — o) on the concentration of
prostaglandin E2 in the medium of synovial fibroblast
cultures. Mean and Standard deviation are given.
1 10 100
Elastase inhibitpr complex [nmol/l]
Fig. 5. Effect of elastase-a2-macroglobulin complexes (o —o)
and elastase-a^proteinase inhibitor complexes (o —o)
pn the concentration of fibronectin in the medium of
synovial fibroblast cultures. Mean and Standard devia-
tion are given.
Discussion
Previous investigations have shown that cells in cul-
ture, grown from the synovial membrane of the knee-
joint, synthesize hyaluronate (äs the predominant
glycosaminoglycan) and proteochondroitin sulphate
(19). Details of the intracellular synthesis of proteo-
glycans have been described previously for different
experimental Systems (27, 28). It has been suggested
that the initiation of biosynthesis of chondroitin sul-
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cul m while the protein core is nascent (29, 30). It is
assumed that the chondroitin sulphate chains are
subsequently assembled mainly in the smooth endo-
plasmic reticulum-Golgi coinplex (31).
Cultured synovial fibroblasts haVe been shown to
distribute newly synthesized radiolabelled glycosami-
noglycans in different compartments f the cell cul-
ture (32, 33). A considerable amount of the radio-
active material is secreted into the culture medium
(extracellular compartment). Glycosaminoglycans of
distinct composition remain in association with the
cell membrane (pericellular compartment) and can
be solubilized by trypsin. Another fraction of the
synthesized macromolecules remains inside the cell
(intracellular compartment), and is either transferfed
into the lysosomes for immediate degradation or
internalized, e.g. by the nucleus and mitochondria
(34, 35). The simultaneous investigation of the intra-j
peri-, and extracellular glycosaminoglycans allows
further insight into partial Steps of metabolism, such
s intracellular synthesis, secretion into the extracellu-
lar medium, reuptake of macromolecules, and intra-
cellular degradation.
In our study, during the incubation of cultured syn-
ovial fibroblasts with elastase-inhibitor eomplexes,
we observed not only an enhancement of total glycos-
aminoglycans in the cell culture, but also a displace-
ment of hyaluronate and chondroitin sulphate be-
tween the three compartments of the cell culture; an
increase of glycosaminoglycans in the extracellular
pool (medium) was accompanied by a corresponding
decrease inside the cells and the pericellular space.
This indicates that elastase-proteinase inhibitor com^
plexes stimulate both the synthesis and secretion of
hyaluronate and chondroitin sulphate. No significant
changes of hyaluronate metabolism and only a slight
increase of the radiolabelled chondroitin sulphate
were found after incubation of the synovial cells with
native elastase.
The cultured synovial celis used in our experiments
cannot be differentiated by light microscopy, but
were possibly eomposed of fibroblast-like and macro-
phage-like cell types, which have been shown to
be present in the synovial membrane by eleetron
microscopy (36). It has been shown that proteinase-
a2-macroglobulin eomplexes are endocytosed by both
tissue macrophages and fibroblasts (37—40). In pre-
vious publications it was reported that large am unts
of a2-macroglobulin could be detected intraeellularly
in normal human fibroblasts cultured in medium
8μρρ1βηΐ6ηΐ6(1 with serum (41). arM croglobulin was
shown to be taken up from the n^edium by the fibro-
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blasts at a remarkably high rate. Kinetic analysis
of this uptake mechanism suggests that exclüsively
complexes of a2-macroglobulin with proteinases were
taken up by the cells (42). Previous results therefore
provide strong evidence for the presence of a protein-
ase-a2-macroglobulin receptor on the cell surface of
fibroblasts (39).
Binding of proteinases to a2-macroglobulin leads to
a drastic conformational change in the a2-macroglo-
bulin resulting in physical entrapment of the protein-
ase. The calcium-dependent specific recognition by a
cell surface receptor of a2-macroglobulin-proteinase
complexes, and not of the native molecule, is most
likely due to this conformational reorganization of
the a2-macroglobulin molecule upon complexation
(40, 43). The entrapment of the proteinase by a2-
macroglobulin suggests that it is the a2-macroglobulin
part of the complex which is recognized by the recep-
tor and not the proteinase. This point is substantiated
by the use of different a2-macroglobulin-proteinase
complexes, i.e. trypsin-a2-macroglobulin and col-
Ia;genase-a2-macroglobulin complexes, which be-
haved quite similarly in uptake studies (42, 44).
Tissue macrophages likewise have surface receptors
that make the uptake and clearance of a2-macro-
globulin-bound proteinases from the extracellular
space possible (38, 40, 45). This receptor System also
only operates when a2-macroglobulin is complexed
with proteinases.
Proteinase-a2-macroglobulin complexes released into
the circulation are believed to be removed rapidly by
reticuloendothelial cells (46). Recent in vitro studies
with rats have shown that the uptake of trypsin-a2-
macroglobulin complex into hepatocytes (85 — 90%)
and Kupffer cells (4—9%) appears to account for the
niajor part of its uptake by the liver and thereby for
its rapid removal from the blood (47). In the joint
cävity, however, which is not in direct contact with
the blood circulation, the proteinase-inhibitor com^
plexes accumulate. During inflammatory processes
the local release of proteinases from phagpcytes, as-
sociated with an enhanced diffusion of plasma a2-
macroglobulin through the blood-synövial fltiid bar-
rier, leads to an iiiteraction of proteinase-a2-macro-
globulin complexes with the surrounding connective
tissue cells of the synovial system.
The uptake of protdnase^a^macroglobulin com-
plexes by tissue macrophages and fibroblasts of the
synovial system initiales a number of biochemical
events, including an enhanced release of prostaglan-
dins, which are detectable in high concentrations in
inflammatory synovial fluids (48).
Macrophages which respond to phlogogenic Stimuli
release large amounts of arachidonic acid oxygena-
tion products and seem to be the main source of
prostaglandins in inflammatory joints. Previous stud-
ies have shown that the challenge of quiescent mouse
peritoneal macrophages with zymosan particles leads
to a burst-like production of prostaglandin E2 and
prostaglandin I2 (49). Endogenous arachidonic acid
present in the membrane phospholipids serves äs sub-
strate. During culturing of phagocytosis-stimulated
macrophages prostaglandins are produced in large
quantities at the initial phase of the Stimulation, and
the release of prostaglandin into the culture medium
appears to cease completely within two days after
activation (50). Resting macrophages produce only
small amounts of prostaglandins.
It has been reported that macrophage-like cells, which
normally make up one third of the lining cells (51),
and are resident macrophages of the synovial mem-
brane, are part of the organism's mononuclear pha-
gocyte system and show many typical biochemical
functions common to tissue macrophages of different
provenance. Endoeytosis of substances by those
macrophages might be accompanied by the produc-
tion of prostaglandins (52, 53).
Exposure of the synovial cells to elastase-inhibitor
complexes leads to an increase of prostaglandin E2
in the culture medium, most pronounced in the
presence of elastase-a2-macroglobulin complexes,
whereas native elastase does not show a significant
effect. Assuming that the cells in culture consist of
fibroblast-like and macrophage-like cells, it is not
known whether the cells secreting prostaglandin E2
are identical with those that are able to synthesize
hyaluronate.
It has been suggested that the endocytotic process in
general, independent of the type of cells, leads to
an increased formation of prostaglandins (52). The
intracellular vacuolisation during endocytosis seems
to correlate and coincide with prostaglandin forma-
tion and might be due to the internalization of mem-
branes containing arachidonic acid-rich phospholip-
ids, äs well äs to the fusion of different cell organelles,
thus providing more Substrate for the generation of
prostaglandins. The increase of prostaglandin E2 in
the synovial fibroblast culture medium during incuba-
tion with elastase-a2-macroglobulin complexes, which
was observed in our study, is probably the conse-
quence of endocytosis of these complexes by the cells
in culture.
The cultured synovial cells produce prostaglandins
and are also at the same time subject to regulation
by prostaglandins* In vitro studies have shown that
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the external addition of prostaglandins to macro-
phages inhibits the metabolic capacity to generate
oxygen-derived radicals and also the phagocytic and
pinocytic functions (54). Furthermore, all data indi-
cate that in particular prostaglandin E2 increases
glycosaminoglycan synthesis in fibroblasts, both in
vivo and in vitro. The actions of the prostaglandins
are probably mediated through increased intracellu-
lar levels of cyclic nucleotides (53, 55). Furthermore,
it has been reported that inhibitors of prostaglandin
synthesis also cause a decrease of hyaluronate syn-
thesis in synovial fibroblasts (19). Thus, from our
studies with cultured synovial cells, it might be con-
cluded that the increased synthesis of hyaluronate
and chondroitin sulphate in the presence of elastase
inhibitor complexes is primarily caused by an en-
hanced release of prostaglandin.
It seems that there is no uptake of elastase-arprotein-
ase inhibitor complexes in macrophages comparable
to that which occurs with a2-macroglobulin com-
plexes (45, 56)! In vitro studies with rabbit alveolar
macrophages have shown a rapid uptake of proteina-
se-tti^-macroglobulin complexes by the cells, but it
has been reported that complexes of labelled trypsin
or subtilopeptidase A with rabbit c^-proteinase inhib-
itor do not become similarly associated with the cell
surface and were not endocytosed. It was also ob-
served that proteinase-di-proteinase inhibitor com-
plexes fail to inhibit the uptake of proteinase-a2-
macroglobulin complexes (56). Thus, ctj-proteinase
inhibitor and a2-macroglobulin-binding provide sep-
arate mechanisms for disposal of proteinases.
Little is known about the uptake of proteinase-ar
proteinase inhibitor complexes, especially of elastase-
arproteinase inhibitor complexes, by fibroblasts.
Whether the enhanced release of prostaglandin and
the increased synthesis and secretion of hyaluronate
in the presence of elastase-cij-proteinase inhibitor
complexes, found in our studies with cultured syn-
ovial cells, is mediated by an endocytotic process is
therefore not yet clear and needs further investiga-
tion. There is also no Information concerning the
uptake of native uncomplexed elastase by fibroblasts.
It has been reported that macrophages and granulo-
cytes specifically bind and ingest unbound elastase
(45, 57, 58). A receptor-mediated endocytosis of elas-
tase by synovial cells, however, seems to be unlikely,
since our investigations have shown that the uncom-
plexed proteinase failed to stimulate glycosaminogly-
can and prostaglandin metabolism.
When we studied the influence of the native protein-
ase inhibitors alone, no significant effect of armacro-
globulin on hyaluronate and chondroitin sulphate
metabolism was detectable. Physiological concentra-
tions of -proteinase inhibitor, however, showed a
strong inhibitory effeot on glycosaminoglycan metab-
olism, particularly with respect to the synthesis of
hyaluronate and its secretion into the extracellular
compartment. The mechanism of Inhibition by ar
proteinase inhibitor is not well understood, and is
probably due to the reaction of the proteinase inhibi-
tor with cell membrane-associated proteinases. Mem-
brane-associated proteinases have been claimed by
several investigators in lymphocytes, granulocytes,
kidney tissue, macrophages (59) and human fibro-
blasts (60). Proteinases, which exhibit the properties
of elastase, have been isolated froin purified cell mem-
branes of human monocytes and lymphocytes (61).
It has also been postülated that such membrane-
bound proteinases may play a dominant role in macro-
phage-mediated degradation of connective tissue
(62). It has been shown that cti-proteinase inhibitor
decreases the mixed lymphocyte response (63), the
activity of killer cells and antibody-dependent cell-
mediated cytotoxicity (64).
The extracellular reaction of elastase with proteinase
inhibitors leads to an almost complete loss of proteo-
lytic activity, but it does not result in the formation of
metabolically inactive protein complexes. Our studies
with synovial cell cultures rather indicate that potent
inflammatory mediators are generated, which seem to
be involved basically in inflammatory joint processes.
Elastase-inhibitor complexes stimulate synovial cell
cultures to show a constellation of fmdings closely
resembling the metabolic activities present in inflam-
matory synovial Systems, including aecelerated syn-
thesis and secretion of hyaluronic acid, increased
formation of prostaglandins, äs well äs an enhanced
glucose consumption and lactic acid production. We
have further shown that exposüre of synovial fibro-
blast cultures to elastase-inhibitor complexes induces
a rise in the fibronectin concentration in the medium,
This finding is also in good agreement with the in
vivo data during an inflammatory joint disease, in
which elevated fibronectin levels were observed in the
synovial fluid but not in the blood plasma (65, 66).
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